Rituximab Clinical Trials
202 recruitingDrug
Phase 2125Phase 149Phase 344Phase 47Not Applicable3
Showing 1–20 of 202 trials
Recruiting
Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
KSHV Inflammatory Cytokine Syndrome (KICS)KSHVHHV-8
National Cancer Institute (NCI)140 enrolled1 locationNCT01419561
Recruiting
Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC594 enrolled126 locationsNCT06890884
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled262 locationsNCT06717347
Recruiting
Phase 2
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Waldenstrom Macroglobulinemia
Massachusetts General Hospital56 enrolled5 locationsNCT06561347
Recruiting
Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Lymphoma, B-Cell
Celgene224 enrolled43 locationsNCT04884035
Recruiting
Phase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center42 enrolled8 locationsNCT06765317
Recruiting
Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled130 locationsNCT04840602
Recruiting
Phase 1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Follicular LymphomaLymphoma Diffuse Large B-cellLymphoma, Non-Hodgkin's
Eli Lilly and Company460 enrolled46 locationsNCT07226843
Recruiting
Phase 3
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.132 enrolled14 locationsNCT07104032
Recruiting
Phase 3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Follicular Lymphoma
The Lymphoma Academic Research Organisation790 enrolled116 locationsNCT06284122
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled173 locationsNCT06943872
Recruiting
Phase 1
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
National Cancer Institute (NCI)47 enrolled54 locationsNCT04609046
Recruiting
Phase 2
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Severe Aplastic AnemiaAcquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell Aplasia+1 more
Masonic Cancer Center, University of Minnesota60 enrolled1 locationNCT06412497
Recruiting
Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Diffuse Large B Cell LymphomaNHLNon-Hodgkin's Lymphoma+1 more
National Cancer Institute (NCI)132 enrolled1 locationNCT04002947
Recruiting
Phase 1Phase 2
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Hairy Cell LeukemiaRecurrent Hairy Cell LeukemiaRefractory Hairy Cell Leukemia
National Cancer Institute (NCI)84 enrolled4 locationsNCT06965114
Recruiting
Phase 2
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Sickle Cell DiseaseThalassemiaThalassemia (beta)
Memorial Sloan Kettering Cancer Center24 enrolled6 locationsNCT05736419
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled132 locationsNCT05139017
Recruiting
Phase 2
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center40 enrolled9 locationsNCT07231952
Recruiting
Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Genmab496 enrolled76 locationsNCT05283720
Recruiting
Phase 3
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology421 enrolled237 locationsNCT05976763